Short-Term Computer-Assisted Quantification of Plus Disease After Treatment of Type 1 Retinopathy of Prematurity with Intravitreal Bevacizumab or Retinal Laser Photocoagulation (original) (raw)

Retinal Cases & Brief Reports

Abstract

To compare objectively measured changes in plus disease after bevacizumab and laser for Type 1 retinopathy of prematurity. ROPtool (a computer program) analyzed fundus images at baseline, 1 week, and subsequent examinations. Six infants (9 eyes) were treated with bevacizumab and 7 (12 eyes) with laser. One week after treatment, bevacizumab compared with laser resulted in a greater median percent change from pretreatment in tortuosity (-53.8 vs. -0.2%, P < 0.001) and overall plus disease (-20.1 vs. -3.1%, P < 0.001). Change in dilation did not differ (-3.5 vs. -5.5%, P = 0.48). After week 1, all median ROPtool parameters continued to decrease for both groups. At last follow-up (median 3, range: 2-10 weeks), both bevacizumab and laser significantly decreased tortuosity (-54.3 and -23.8%), dilation (-8.7 and -7.5%), and overall plus disease (-27.3 and -10.3%). Improvement in plus disease, in particular tortuosity, likely occurs more quickly after bevacizumab compared with laser, particularly at 1 week after treatment. These results guide clinical expectations for plus disease resolution after both treatment modalities.

Kevin Gertsch hasn't uploaded this paper.

Let Kevin know you want this paper to be uploaded.

Ask for this paper to be uploaded.